drugset / Trial / NCT02332499
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-08-18
- Completion
- 2019-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Catequentinib | Small molecule | — | Oral |